Introduction
Primary dysmenorrhoea is one of the commonest gynaecological complaints and is a major cause of loss of work in young women. No consistently effective treatment has yet been devised, other than the use of antiovulatory oral contraceptives, a choice that is not always acceptable for obvious reasons. The etiology of primary dysmenorrhoea is not known, although many theories for its cause have been advanced.
There is increasing evidence to suggest that prostaglandins of the E and F series may be involved in the pathogenesis of dysmenorrhoea (Pickles, Hall, Best & Smith, 1965; Willman, Collins & Clay'ton, 1976; Chan & Hill, 1978) . Discharge of endometrial prostaglandins may contribute to the cramps of dysmenorrhoea, and possibly to 'menstrual diarrhoea' as well. Recent clinical reports indicate that non-steroidal anti-inflammatory drugs which inhibit the enzyme complex, prostaglandin synthetase, are of value in the treatment of primary dysmenorrhoea (Schwartz, Zor, Lindner & Naor, 1974; Anderson, Haynes, Fraser & Turnbull, 1978; Halbert, Demers, Fontanna & Darnell Hones, 1978; Kapadia & Elder, 1978) .
Flurbiprofen is a new and one of the most powerful of the anti-inflammatory agents in inhibiting the action of prostaglandin synthetase in various tissue systems (Blackham & Owen, 1975; Crook, Collins, Bacon & Chan, 1976) . This feature of flurbiprofen prompted us to evaluate its efficacy in comparison with aspirin and placebo in the treatment of prima-ry dysmenorrhoea.
Methods
Resident staff and student nurses aged between 14-26 years and suffering from primary dysmenorrhoea for at least 3 months were selected for the study. Nurses who gave a history of dyspepsia or peptic ulceration and those who were taking oral contraceptives were excluded from the trial. The severity of pain of dysmenorrhoea when untreated was categorised as: moderate-pain though bearable produces some inhibition of normal activities; severe-pain, very distressing, severely limiting normal activities at least for 1 day; very severe-pain, worse, producing complete cessation of normal activities and necessity for bed rest at least for 1 day. Patients who complained of mild pain during previous periods were not included in the study.
Each patient received all three drugs, one at each menstrual period, as per order of drug administration given in Table 1 . The three drugs, flurbiprofen, aspirin and placebo were administered as capsules of 00 Macmillan Journals Ltd. 1980 0306-5251/80/060605-04 $01.00 The nature of the trial was explained to all patients after an initial interview during which a full medical and gynaecological history was noted. The patients were instructed to take two capsules of trial medication at the onset of dysmenorrhoea and continue taking two capsules at 8 hourly intervals until the symptoms disappeared. Aspirin was administered 8 hourly to maintain double-blind nature of the trial. Each patient was asked to fill up a self-assessment card which was provided to her during the menstrual period under study, and was asked to see the same clinician after each menstrual period.
The degree of pain relief obtained during treatment was graded as: 4-complete relief, when there was no pain at all; 3-marked relief, when pain was dull and there was no restriction of activities; 2-moderate relief, when pain was mild and there was some restriction of normal activities; 1-slight relief, when there was some relief and restriction of normal activities; 0-no relief. Each patient was instructed to assess the degree of pain relief obtained with each trial drug treatment, based on her previous experience of dysmenorrhoea, when untreated.
Blood loss, whether more, or less or same as compared to pre-trial menstrual blood loss was also recorded.
Any symptoms which may be related to the treatment were also noted down. The clinician's overall assessment of the efficacy of treatment was based on an interview with the patients regarding symptomatic relief obtained during each drug treatment. Efficacy of trial medication was graded as: 3-excellent; 2-good; 1-fair and 0-poor. indicating specific analgesic action of the drug.
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In conclusion, the analgesic effect of flurbiprofen seen in this study establishes the therapeutic usefulness of the drug in the symptomatic treatment of primary dysmenorrhoea.
